Navigation Links
Santaris Pharma - Interim Report for the Period 1 January to 30 June 2009
Date:7/14/2009

he Company expects to publicize the encouraging results of this study in the 2nd half of the year. An IND regarding a Phase I multiple dose clinical study with SPC3649 in healthy volunteers has been submitted and the trial is scheduled to be commenced later in 2009. Further a three months tox study will be initiated during the 2nd half of 2009.

EZN2968-HIF-1alpha

Santaris Pharma's collaboration partner Enzon Pharmaceuticals announced preliminary results of the jointly developed Hif-1alpha inhibitor targeting solid tumors at the AACR meeting in May. Enzon expects to report the results of its phase I clinical trials targeting solid tumors with EZN2968 in the 2nd half of 2009. Further Enzon has announced its intention of initiation of a phase II trial with this compound later in 2009.

SPC2996-CLL

In accordance with Santaris Pharma's refocusing of own development activities within metabolic disorders and infectious diseases, it has been decided to divest the activities within the development of SPC2996 targeting CLL. This process is ongoing.

EZN3042-Survivin

In February 2009 Santaris Pharma's collaboration partner Enzon Pharmaceuticals initiated a phase I clinical trial in solid tumors with the LNA-based drug Survivin targeting cancer.

SPC4955-ApoB inhibitor

Santaris Pharma has in rodent and primate studies shown that ApoB inhibitors are able to lower LDL cholesterol and triglycerides effectively. In Q2 2009 the Company selected a lead candidate SPC4955 for preclinical development.

PCSK9-inhibitors

Santaris Pharma has selected lead candidates targeting PCSK9 related to high cholesterol. These candidates are ready for pharmacological studies.

Collaborations

Santaris Pharma has collaboration agreements with three partners, covering up to 22 novel LNA-based RNA therapeutics:


'/>"/>

SOURCE Santaris Pharma
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Santaris Pharma to Present at 10th Annual Biotechnology Industry Organisation CEO & Investor Conference - February 11th, 2008
2. Santaris Pharma Delivers Six LNA-Based RNA Inhibitors to Enzon Pharmaceuticals Ahead of Schedule
3. Santaris Pharma Director Appointed Adjunct Professor in RNA Biology at the University of Aalborg, Denmark
4. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
5. Pharmatek Adds Cytotoxic and High-Potent Drug Development Capabilities to San Diego Laboratory
6. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
7. Skystar Bio-Pharmaceutical Announces Second Quarter 2007 Results
8. Proceedings to Affirm Merger Between PharmAthene and Healthcare Acquisition Corp Initiated in Delaware Chancery Court
9. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
10. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
11. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... 4, 2015 GliaCure, a privately-held biotechnology ... for neurological and neuropsychiatric disorders based on glial ... Alzheimer,s patients in a Phase 1b clinical trial ... developed as a potential disease-modifying treatment. GliaCure,s innovative ... that it both promotes the clearance of amyloid ...
(Date:5/4/2015)... - Fluorinov Pharma (Fluorinov), a FACIT portfolio company, ... Roger J Garceau, to its Board of Directors. ... including corporate development and clinical strategy, his appointment ... expertise as Fluorinov transitions to clinical development.  ... pharmaceutical development experience to Fluorinov and most recently ...
(Date:5/4/2015)... 2015 Genedata, a leading provider ... life science research, today announced the release of ... of its enterprise solution for biologics R&D. This ... efficient discovery and development of novel biotherapeutics. Version ... address protein optimization and developability requirements. Genedata will ...
(Date:5/4/2015)... HONG KONG , May 4, 2015 ... or the "Company"), China,s leading ... cell processing and stem cell storage services, today announced ... Holdings Limited ("Golden Meditech"), a Hong Kong ... the Company, has entered into an agreement (the "Agreement") ...
Breaking Biology Technology:GliaCure Initiates Phase 1b Dosing in Alzheimer's Patients 2Roger J Garceau joins Fluorinov board, adds clinical expertise to bromodomain program and oncology pipeline 2Roger J Garceau joins Fluorinov board, adds clinical expertise to bromodomain program and oncology pipeline 3Genedata Biologics 5.0 – Antibody Engineering and Developability Assessment Advances 2Genedata Biologics 5.0 – Antibody Engineering and Developability Assessment Advances 3Genedata Biologics 5.0 – Antibody Engineering and Developability Assessment Advances 4China Cord Blood Corporation Receives Notice of a Transaction Regarding its 7% Senior Convertible Notes Due 2017 Held by KKR 2China Cord Blood Corporation Receives Notice of a Transaction Regarding its 7% Senior Convertible Notes Due 2017 Held by KKR 3
... -- 3SBio Inc. (NASDAQ: SSRX ) ... company focused on researching, developing, manufacturing and marketing ... its first quarter 2011 unaudited financial results after ... 11, 2011 at 8:00pm (US Eastern ). ...
... that a new market research report is available in ... Global Markets http://www.reportlinker.com/p0488650/Medical-Enzymes-Technologies-and-Global-Markets.html ... growing. The global market for medical enzymes is estimated ... at a compound annual growth rate (CAGR) of 3.9%, ...
... Novavax, Inc. (Nasdaq: NVAX ) will report financial ... 9, 2011, before the U.S. financial markets open.  The announcement ... by Stanley C. Erck, President and Chief Executive Officer, and ... The webcast and conference call will be ...
Cached Biology Technology:3SBio Inc. Schedules Unaudited First Quarter 2011 Results 2Reportlinker Adds Medical Enzymes: Technologies and Global Markets 2Reportlinker Adds Medical Enzymes: Technologies and Global Markets 3Reportlinker Adds Medical Enzymes: Technologies and Global Markets 4Reportlinker Adds Medical Enzymes: Technologies and Global Markets 5Reportlinker Adds Medical Enzymes: Technologies and Global Markets 6Reportlinker Adds Medical Enzymes: Technologies and Global Markets 7Reportlinker Adds Medical Enzymes: Technologies and Global Markets 8Reportlinker Adds Medical Enzymes: Technologies and Global Markets 9Reportlinker Adds Medical Enzymes: Technologies and Global Markets 10Reportlinker Adds Medical Enzymes: Technologies and Global Markets 11Reportlinker Adds Medical Enzymes: Technologies and Global Markets 12Reportlinker Adds Medical Enzymes: Technologies and Global Markets 13
(Date:4/14/2015)... April 14, 2015  HYPR Corp. today announced ... ® ) Alliance tm , an industry consortium ... commit to share technology and collaborate to deliver ... interoperable, more secure and private, and easier to ... verification that protects sensitive user information and eliminates ...
(Date:4/13/2015)... April 13, 2015  higi, a leading cloud-based consumer ... more fully engage with their communities around health and ... protected and secure API.  ... most accessible, affordable, and convenient vehicle to receive validated ... The API will allow higi,s trusted ...
(Date:4/8/2015)... N.C. , April 8, 2015  Infinisource, ... solutions and services, and Morpho, a leading supplier ... partnership to produce the market,s most advanced biometrically-enabled ... Infinisource,s iSolved NXG time clock is setting a ... and labor data for the small and mid-size ...
Breaking Biology News(10 mins):HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 2higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 3iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 3
... of life, and occurs naturally in soil and ground water ... has been linked to lung, bladder and kidney cancer, and ... in drinking water. Chemically similar to phosphorus, arsenic forms arsenate ... 4 3- ). Arsenate interferes with many phosphate-requiring metabolic ...
... April 8 to 10, 2010, 185 attendees from 25 ... new tools to humanely and effectively manage populations of ... biology and other related scientific disciplines presented the newest ... health drug development. Veterinary leaders joined with animal welfare ...
... CORVALLIS, Ore. Forestry scientists at Oregon State University ... rate and other characteristics of trees can be changed ... is conceptually similar to traditional plant breeding. Cisgenics ... sexually compatible. If governments choose to regulate it similarly ...
Cached Biology News:Arsenic hyperaccumulating ferns: How do they survive? 2Arsenic hyperaccumulating ferns: How do they survive? 3Momentum builds after 4th International Symposium on Pet Contraception 2Momentum builds after 4th International Symposium on Pet Contraception 3Success with 'cisgenics' in forestry offers new tools for biotechnology 2Success with 'cisgenics' in forestry offers new tools for biotechnology 3
D.R. Harper (1993) • Includes: essential information on taxonomy, culture and safe handling of viruses, immunology, monoclonal antibodies, antivirals and vaccines....
...
Performance, mycoplasma, virus, and endotoxin tested. Collected from calves 14 days old or less...
...
Biology Products: